Evidence map›Paper›PMID 41020996›Full record

ReviewAnnals of hematology2025

Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature.

Yiling Dai, Yuan Ai, Shuwen Sun, Maoting Tang, Jinrong Li, Ju Gao, Mingyan Jiang

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yiling DaiDepartment of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, No. 20 3rd Section Renmin South Road, Chengdu, 610041, Sichuan, China.
Yuan AiDepartment of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, No. 20 3rd Section Renmin South Road, Chengdu, 610041, Sichuan, China.
Shuwen SunDepartment of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, No. 20 3rd Section Renmin South Road, Chengdu, 610041, Sichuan, China.
Maoting TangKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, Sichuan, 610041, China.
Jinrong LiKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, Sichuan, 610041, China.
Ju Gao *Department of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, No. 20 3rd Section Renmin South Road, Chengdu, 610041, Sichuan, China.
Mingyan Jiang *Department of Pediatric Hematology and Oncology, West China Second University Hospital, Sichuan University, No. 20 3rd Section Renmin South Road, Chengdu, 610041, Sichuan, China. jiangmy0904@163.com.

Funding

Sichuan Medical Association S23008
6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) with erythropoietin receptor (EPOR) gene rearrangement is rarely reported. These patients test negative for the Philadelphia chromosome but exhibit a gene expression profile similar to that of Philadelphia chromosome-positive acute lymphoblastic leukemia, leading to their designation as Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). EPOR-rearranged ALL exhibits aggressive clinical course and dismal prognosis with a short remission duration and high level of minimal residual disease (MRD). The addition of tyrosine kinase inhibitors or Janus kinases inhibitors to conventional chemotherapy is an effective treatment approach for patients with Ph-like ALL. Here, we present two pediatric cases of Ph-like ALL with EPOR rearrangement that were treated with ruxolitinib and provide a literature review to assess the effectiveness of this treatment.

Indexed as

Gene RearrangementPrecursor Cell Lymphoblastic Leukemia-LymphomaPyrazolesReceptors, ErythropoietinChildHumansNitrilesPhiladelphia ChromosomePyrimidinesNitrilesPyrazolesPyrimidinesReceptors, ErythropoietinruxolitinibClinical trialsEPOR rearrangementsMolecular targeted therapyPh-like acute lymphoblastic leukemiaRuxolitinib

Identifiers

PMID41020996
PMCPMC12619797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.